235 East 42nd Street
About Pfizer, Inc.
Imagine touching the lives of people everywhere. Imagine reaching beyond the ordinary and impacting something greater than the bottom line. Imagine influencing some of the most critical issues facing healthcare today.
At Pfizer Global Research & Development (PGRD), Pfizer’s visionary discovery and development division and the largest research-based biomedical and pharmaceutical company in the world, we're not content waiting to witness the evolution of our industry. Instead, we’re driven by science, building on our current successes and capabilities, playing a critical role in developing the most compelling story of scientific discoveries.
To date, PGRD has brought to market a wide range of medicines, such as Lipitor® (atorvastatin calcium), Zithromax® (azithromycin), Viracept® (nelfinavir mesylate), Zoloft® (sertraline hydrochloride), Viagra® (sildenafil citrate), and our newest smoking cessation medicine, Chantix® (varenicline). And, today, with a broad research pipeline that spans many therapeutic areas, we are determined to bring even more cures to the marketplace.
But there is much more work to be done and we can’t do it alone. We’re always seeking those who share our belief that science can improve our world, that by working together we can bring exciting new therapies to patients on a global scale and forever change the way we improve the health and well-being of all people.
Why Join Pfizer?
Pfizer offers the opportunity to work on promising research, access to unparalleled resources and world-class facilities, and the chance to work with some of the brightest and most driven individuals in the pharmaceutical industry.
At Pfizer, we build our success on the innovation, skills, and entrepreneurial spirit of each of our colleagues. As an integral member of our team, you'll find myriad opportunities to assert your professional independence as you generate results that will advance our ultimate goal of creating life-enhancing therapies.
In addition to creating the environment for innovation, our values have led to numerous corporate awards acknowledging excellence in many domains - with investors, our business partners, and our employees. We've been praised as “One of the 100 Best Companies for Working Mothers” by Working Mother® Magazine (9/07), honored with “The Best Employers for Healthy Lifestyles 2007 Award” by the National Business Group on Health (5/07), and awarded by the Women's Business Enterprise National Council on its annual listing of America's Top Corporations for Women's Business Enterprises (3/07).
At PGRD, your success is critical to our success. PGRD offers world-class career opportunities, directing resources and time that result in a high-level scientific professional track. Our employees and external rankings with the leading authorities attest to the fact that PGRD is one of the best companies to work for - where you choose a lifestyle - not just a job.
• La Jolla, CA
Located north of downtown San Diego, La Jolla boasts southern California's most beautiful and majestic coastline, with an abundance of cultural, outdoor recreation, and big city activities. Home to Salk Institute and Scripps Research Institute - two renowned academic institutions - and many major biotechnology and telecommunications firms, La Jolla offers a rich environment for both scientists and engineers.
• New London and Groton, CT
Located on the southeastern Connecticut seashore in a historical New England vacation area known for its seafood, easy pace of living, and nautically related recreational activities. It's also within reasonable driving distance to a wealth of greater academic institutions, and within a couple of hours of Boston and New York.
• St. Louis, MO
Known as the Gateway to the West, St. Louis is a diverse, vibrant metropolitan area of 2.5 million, with a broad-based economy. Residents enjoy professional sports teams, a world-class symphony orchestra, botanical gardens, and numerous other outdoor activities. Additionally, scientists have the opportunity to collaborate with researchers at Washington University School of Medicine.
• Sandwich, UK
Sandwich, once a major port in England but now 2 miles from the sea, is one of the best-preserved Medieval towns in the UK, with its old town walls and "Kent Peg" roof houses. Situated close to the city of Canterbury and only 80 miles from London, the area is steeped in history and is ideal for those who enjoy water sports. The rail links across the English Channel also mean that you can be in France within an hour, providing access to the whole of Europe.
At PGRD, we celebrate the talents and diversity of our employees. We respect our employees' lives and provide a multitude of resources and supports to help foster a work/life balance. Also, in addition to our outstanding career opportunities and quality of life, we offer a wide array of topnotch and leading-edge benefits, competitive compensation, and exceptional long-term financial rewards designed to ensure your well-being and financial security. We offer you choices so you can craft a plan that meets your individual and family needs.
Your talent can change the world. Join us.
To learn more about our people, our products, and our plans for the future, visit www.pfizer.jobs
We’re proud to be an equal opportunity employer and welcome applications from people with different experiences, backgrounds, and ethnic origins.
Founder: Charles Pfizer
CEO: Ian C. Read
CMO: Freda C. Lewis-Hall, M.D., DFAPA
CFO: Frank D’Amelio
Please click here for clinical trial information.
For more information, visit
www.pfizer.com and follow us on www.twitter.com/Pfizer.
Tweets by Pfizer
Innovating for Healthier Lives
3853 articles with Pfizer, Inc.
Kymera Therapeutics secured $65 million in a Series B funding round that was supported, in part, by the investment arms of Pfizer and Sanofi.
Viagra and Cialis: PDE-5 Inhibitors May Have Broader Applications in Cancer, Neurology and Cardio...
11/13/2018Viagra (sildenafil), Pfizer’s blockbuster drug for erectile dysfunction, is a classic example of how a drug developed for one thing can turn out to be successful for another.
The pharma industry began to push back against the presidential blueprint for drug prices ahead of the election. Will that continue with a now divided Congress?
New Clinical Oncology Collaboration Between Nektar and Pfizer to Evaluate Combination of NKTR-214, a CD122-Biased Agonist, with Avelumab and Talazoparib or Enzalutamide in Multiple Cancers
Nektar Therapeutics announced that it has entered into an oncology clinical collaboration with Pfizer Inc. to evaluate several combination regimens in multiple cancer settings, including metastatic castration-resistant prostate cancer (mCRPC) and squamous cell carcinoma of the head and neck (SCCHN).
While many consider failure to be a completely negative experience, that’s not always the case, as every failure is still a lesson learned. Occasionally, these failures can even lead to some of the biggest breakthroughs in medical history.
Nektar Therapeutics, based in San Francisco, and New York-based Pfizer are teaming up to evaluate combination regimens in several cancer settings. Those include metastatic castration-resistant prostate cancer (mCRPC) and squamous cell carcinoma of the head and heck (SCCHN).
The U.S. FDA approved Pfizer’s Lorbrena (lorlatinib) for ALK-positive metastatic non-small cell lung cancer (NSCLC) in patients whose disease hasn’t progressed on crizotinib and at least one other ALK inhibitor or for patients whose disease has progressed on alectinib or ceritinib as the first AL...
11/5/2018Biopharma companies make key appointments to fill leadership positions. Let's take a look!
Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved LORBRENA® [lor-BREN-ah] (lorlatinib)
To suggest that the pharma industry is a reluctant partner in President Donald Trump’s attempts to decrease drug prices is to overstate the fact. But now the industry appears to be pushing back, at least a little bit.
Third-Quarter 2018 Revenues of $13.3 Billion, Reflecting 2% Operational Growth
Privately-held Grunenthal GmbH will pay AstraZeneca $700 million for the prescription medicine rights to acid-reflux medicine Nexium. The deal with AstraZeneca represents the largest investment in Grünenthal company history.
According to Jay Bradner, president of the Novartis Institutes for Biomedical Research, the company is cutting its drug programs from 430 to 340. One of the big areas the company is abandoning is infectious diseases. The decision is a result of a strategic review by Vasant (Vas) Narasimhan, the c...
Joint studies will evaluate one or more of Pfizer’s investigational NASH therapies in combination with Novartis’s FXR agonist for the treatment of the progressive liver disease
NASH is similar to cirrhosis of the liver but occurs in people that drink little or no alcohol. It is related to the obesity epidemic and affects at least three to five percent of the adult population worldwide. Many believe that combination therapies will be the best way to approach treating NAS...
10/29/2018Biopharma companies shore up leadership roles with new hires and appointments, at Axcella Health, Twist Bioscience, and more.
It has been six years since Johnson & Johnson first launched its JLABS incubators for the life science industry with a vision of providing assistance to startups that could potentially bring about a new paradigm of care for patients.
As part of a plan to lower prescription drug prices for millions of Americans, President Donald Trump is set to announce a sweeping plan to overhaul how Medicare pays for medication.
Eli Lilly and Company and Pfizer presented complete results from a Phase III clinical trial of tanezumab in patients with osteoarthritis (OA) at the 2018 American College of Rheumatology/Association of Rheumatology for Health Professionals (ACR/ARHP) Annual Meeting in Chicago.
John D. Arnold, a billionaire hedge fund manager who made his fortune on energy stocks, is now taking on the cost of high prescription drugs. The Texas-based Arnold has spent more than $100 million on health-related grants since 2014, with a significant portion dedicated to cheaper medications.